The Company and list of its subsidiaries consolidated in current year and as of the report date were shown below: | Name of entity | | Place of
incorporation | | Ownership
interest as of
June 30,
2026 | | Ownership
interest as of
June 30,
2025 | | Principal activities | | Advanced Biomed Inc. | | Nevada, United States | | N/A | | N/A | | Investment holding | | Acellent Technologies (Hong Kong) Co. Limited (1) | | Hong Kong | | 100% | | — | | Artificial intelligence and financial algorithmic software-related activities and agency services | | Advanced Biomed Inc. (Taiwan) (2) | | Taiwan | | — | | 100% | | Research and development of microfluidic technologies and cancer screening-related medical device applications | | Advanced Biomed HK Limited (3) | | Hong Kong | | — | | 100% | | Investment holding in the biotechnology sector | | Shanghai Sglcell Biotech Co., Ltd. (3) | | Mainland China | | — | | 100% (indirect) | | Biotechnology-related market development and clinical activities | | (1) | The Company acquired 100% of the equity interests in Acellent Technologies (Hong Kong) Co. Limited in April 2026. | | (2) | The Company disposed of its entire equity interest in Advanced Biomed Inc. (Taiwan) on June 30, 2026. | | (3) | The Company disposed of its entire equity interest in Advanced Biomed HK Limited, including its wholly owned subsidiary, Shanghai Sglcell Biotech Co., Ltd., in December 2025. |
|